Literature DB >> 10837181

Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

C Clairmont1, K C Lee, J Pike, M Ittensohn, K B Low, J Pawelek, D Bermudes, S M Brecher, D Margitich, J Turnier, Z Li, X Luo, I King, L M Zheng.   

Abstract

VNP20009 is a genetically modified strain of Salmonella typhimurium possessing an excellent safety profile, including genetically stable attenuated virulence (a deletion in the purI gene), reduction of septic shock potential (a deletion in the msbB gene), and antibiotic susceptibility. VNP20009 is genetically stable after multiple generations in vitro and in vivo. In mice, VNP20009 is rapidly cleared from the blood from a peak level of 1x104 cfu/mL to undetectable levels in 24 h. In tumor-bearing mice, VNP20009 accumulates preferentially in tumors over livers at a ratio of 1000&rcolon;1. In nonhuman primates, VNP20009 was also rapidly cleared from the blood, from a peak level of 1.0x106 cfu/mL to undetectable levels in 24 h. VNP20009 was detected in the liver, spleen, and bone marrow of monkeys; the amount decreased over time, and VNP20009 was cleared from all organs by day 41; no VNP20009 could be detected in the urine or feces of the monkeys. VNP20009 is genetically stable after many generations of growth (>140) both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837181     DOI: 10.1086/315497

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  104 in total

1.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant.

Authors:  Qingke Kong; David A Six; Qing Liu; Lillian Gu; Kenneth L Roland; Christian R H Raetz; Roy Curtiss
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

3.  Advances in bacterial cancer therapies using synthetic biology.

Authors:  Tiffany Chien; Anjali Doshi; Tal Danino
Journal:  Curr Opin Syst Biol       Date:  2017-05-23

Review 4.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

Review 5.  Bacterial type III secretion system as a protein delivery tool for a broad range of biomedical applications.

Authors:  Fang Bai; Zhenpeng Li; Akihiro Umezawa; Naohiro Terada; Shouguang Jin
Journal:  Biotechnol Adv       Date:  2018-02-02       Impact factor: 14.227

Review 6.  The bacterial instrument as a promising therapy for colon cancer.

Authors:  Atieh Yaghoubi; Majid Khazaei; Amir Avan; Seyed Mahdi Hasanian; Saman Soleimanpour
Journal:  Int J Colorectal Dis       Date:  2020-03-04       Impact factor: 2.571

7.  Tumor-specifically hypoxia-induced therapy of SPRY1/2 displayed differential therapeutic efficacy for melanoma.

Authors:  Zhipeng Liu; Xiufeng Liu; Wenmin Cao; Zi-Chun Hua
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

8.  Attenuated Salmonella engineered with an apoptosis-inducing factor (AIF) eukaryotic expressing system enhances its anti-tumor effect in melanoma in vitro and in vivo.

Authors:  Huan Wang; Tingtao Chen; Linxi Wan; Jiachen Lu; Hong Wei; Ke-Yu Deng; Jing Wei; Hong-Bo Xin
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-24       Impact factor: 4.813

9.  Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model.

Authors:  Brent Sorenson; Kaysie Banton; Lance Augustin; Sean Barnett; Karen McCulloch; Joshua Dorn; Natalie Frykman; Arnold Leonard; Daniel Saltzman
Journal:  Biologics       Date:  2010-03-24

10.  Inhibition of hepatitis B virus gene expression and replication by ribonuclease P.

Authors:  Chuan Xia; Yuan-Chuan Chen; Hao Gong; Wenbo Zeng; Gia-Phong Vu; Phong Trang; Sangwei Lu; Jianguo Wu; Fenyong Liu
Journal:  Mol Ther       Date:  2013-03-12       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.